Home
Storia in 1 fonti
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate
Raccontata da
morningstar.com
Timeline cronologica
- ·
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate
- ·
Fresenius Announces FDA and EMA Acceptance for Review of Vedolizumab Biosimilar Candidate
Fresenius Announces FDA and EMA Acceptance for Review of Vedolizumab Biosimilar Candidate